Protagenic Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Garo H. Armen
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 149 Fifth Avenue New York City NY United States of America 10010
- IPO Date
- Apr 27, 2021
- CIK
- 0001022899
- Website
- protagenic.com
- Similar Companies
- Business
- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics targeting stress-related neuropsychiatric disorders, central nervous system conditions, epilepsy, obesity, and metabolic disorders. The company offers a diversified pipeline of peptide-based and cannabinoid therapeutics, including its lead clinical-stage asset PT-00114, a synthetic teneurin carboxy-terminal associated peptide (TCAP) in Phase I/IIa targeting post-traumatic stress disorder, treatment-resistant depression, generalized anxiety disorder, and substance use disorders via the biologics license application pathway; PHYX-001, a preclinical potassium channel modulator; multiple cannabinoid-based compounds with composition-of-matter intellectual property for central nervous system and cardiometabolic indications, including a proprietary obesity and metabolic dysfunction candidate competing with GLP-1 agonists; and modified stilbenoid compounds demonstrating preclinical anticonvulsant activity. Protagenic Therapeutics operates primarily in the United States with preclinical and early clinical programs addressing large unmet needs in neuropsychiatry and neurology. Founded in 1994 and headquartered in New York, New York, the company completed a transformative business combination with Phytanix Bio Inc. on May 19, 2025, expanding its pipeline from a single asset to six complementary drug candidates and integrating cannabinoid development expertise from former GW Pharmaceuticals team members experienced with Epidiolex and Sativex; subsequent warrant exchanges raised $3.1 million in May 2025 to fund pipeline advancement; and a 1-for-14 reverse stock split occurred on May 5, 2025.
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX)
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
Atrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy?
Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX)
Results from Phase 1 Multiple-Dose Study of PT00114
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
Atrinsic (NASDAQ:PTIX) Trading Up 2.5% – Time to Buy?
Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split